Randomised controlled trials investigating the use of rFVIIa in trauma
| Author, Year | Patient group | Intervention | Study type | Outcomes | Key results | Comments |
| Boffard, 200517 | 143 blunt trauma patients requiring >6 units of blood | Three doses of intravenous rFVIIa or placebo, 200 μg/kg, 100 μg/kg, 100 μg/kg at time zero, 1 h and 3 h | Randomised, blinded placebo-controlled trial | Number of units RBCs transfused over next 48 h. Also survival and adverse events | No difference in survival. Reduction in RBC transfusion in rFVIIa group (reduced by 2.6 units) | |
| Boffard, 200517 | 134 penetrating trauma patients requiring >6 units of blood | Three doses of intravenous rFVIIa or placebo, 200 μg/kg, 100 μg/kg, 100 μg/kg at time zero, 1 h and 3 h | Randomised, blinded placebo-controlled trial. | Number of units RBCs transfused over next 48 h. Also survival and adverse events | No difference in survival or any other measured outcome | |
| Hauser, 201018 | 573 trauma patients requiring between 4 and 8 units RBCs in the first 12 h following injury | Three doses of intravenous rFVIIa or placebo, 200 μg/kg, 100 μg/kg, 100 μg/kg at time zero, 1 h and 3 h | Randomised, blinded placebo-controlled trial | 30-day mortality | No difference in mortality between groups. No difference in adverse events | Trial stopped due to lower mortality than predicted in trial study group |